| Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer. | |
| | |
MedLine Citation:
|
PMID: 18243403 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
It has been analyzed the frequency of p16 inactivation in 67 blood samples of patients diagnosed with advanced non-small cell lung cancer (NSCLC), to establish the relationship between p16 inactivation and time to progression (TTP) and overall survival (OS), and its relationship with various clinical parameters. This is a retrospective study of 67 patients diagnosed with advanced NSCLC between August 2000 and July 2003 in the Hospital General de Valencia analysing p16 inactivation by assessing in plasma either loss of heterozygosity (LOH) or p16 promoter methylation. The study shows p16 inactivation in 28.3% (either by LOH or by p16 methylation). No significant differences were found between the group with p16 inactivation and the group without p16 inactivation, either in patients' TTP (31 weeks vs. 24 weeks; p=0.7) or in OS (53 weeks vs. 43 weeks; p=0.48). No relationship was found between the state of p16 and the clinical parameters analyzed (stage, ECOG, histology). Despite the fact that p16 is important in NSCLC carcinogenesis, the data obtained in our study do not allow the prognostic impact of this biological marker to be established. |
| | |
Authors:
|
Rafael Sirera; Mireia Gil; Ana Blasco; Andrea Cabrera; María José Safont; Vega Iranzo; Diego Cayuela; Rafael Rosell; Carlos Camps |
Related Documents
:
|
15961513 - Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional... 15386433 - Aberrant promoter methylation of human dab2 interactive protein (hdab2ip) gene in lung ... 15274363 - Presence of human papillomavirus in tonsillar cancer is a favourable prognostic factor ... |
Publication Detail:
|
Type: Journal Article Date: 2008-02-19 |
Journal Detail:
|
Title: Lung cancer (Amsterdam, Netherlands) Volume: 61 ISSN: 0169-5002 ISO Abbreviation: Lung Cancer Publication Date: 2008 Jul |
Date Detail:
|
Created Date: 2008-06-30 Completed Date: 2008-09-16 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 8800805 Medline TA: Lung Cancer Country: Ireland |
Other Details:
|
Languages: eng Pagination: 104-8 Citation Subset: IM |
Affiliation:
|
Servicio de Oncología Médica, Hospital General Universitario, Valencia, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung / blood*, genetics*, mortality DNA Methylation Disease-Free Survival Female Genes, p16* Humans Kaplan-Meiers Estimate Loss of Heterozygosity Lung Neoplasms / blood*, genetics*, mortality Male Middle Aged Prognosis Promoter Regions, Genetic Retrospective Studies Tumor Markers, Biological / analysis* Tumor Suppressor Protein p14ARF / blood, genetics |
| Chemical | |
Reg. No./Substance:
|
0/Tumor Markers, Biological; 0/Tumor Suppressor Protein p14ARF |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Next Document: Complete radiographic response of primary pulmonary angiosarcomas following gemcitabine and taxotere...